AVEO Pharmaceuticals, Inc. (AVEO) Given Consensus Rating of “Hold” by Brokerages

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has been assigned an average rating of “Hold” from the eight research firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $4.38.

AVEO has been the topic of a number of recent research reports. BidaskClub downgraded AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 9th. Zacks Investment Research raised AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. initiated coverage on AVEO Pharmaceuticals in a research report on Wednesday, November 15th. They issued a “buy” rating and a $5.00 target price on the stock. Finally, B. Riley initiated coverage on AVEO Pharmaceuticals in a research report on Monday, November 13th. They issued a “buy” rating and a $5.00 target price on the stock.

Shares of AVEO Pharmaceuticals (NASDAQ AVEO) opened at $3.03 on Thursday. The company has a quick ratio of 2.33, a current ratio of 2.33 and a debt-to-equity ratio of -0.32. The stock has a market capitalization of $358.47, a PE ratio of -4.27 and a beta of 1.30. AVEO Pharmaceuticals has a 12-month low of $0.50 and a 12-month high of $4.24.

AVEO Pharmaceuticals (NASDAQ:AVEO) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. The company had revenue of $4.61 million during the quarter, compared to analyst estimates of $6.50 million. research analysts expect that AVEO Pharmaceuticals will post -0.66 EPS for the current year.

Several large investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. acquired a new stake in shares of AVEO Pharmaceuticals in the third quarter valued at about $164,000. Essex Investment Management Co. LLC increased its position in AVEO Pharmaceuticals by 34.1% during the fourth quarter. Essex Investment Management Co. LLC now owns 202,004 shares of the biopharmaceutical company’s stock worth $564,000 after buying an additional 51,384 shares during the last quarter. Rehmann Capital Advisory Group acquired a new position in AVEO Pharmaceuticals during the third quarter worth approximately $193,000. OxFORD Asset Management LLP acquired a new position in AVEO Pharmaceuticals during the third quarter worth approximately $228,000. Finally, California Public Employees Retirement System increased its position in AVEO Pharmaceuticals by 360.6% during the fourth quarter. California Public Employees Retirement System now owns 153,845 shares of the biopharmaceutical company’s stock worth $429,000 after buying an additional 120,445 shares during the last quarter. 50.96% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “AVEO Pharmaceuticals, Inc. (AVEO) Given Consensus Rating of “Hold” by Brokerages” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/08/aveo-pharmaceuticals-inc-aveo-given-consensus-rating-of-hold-by-brokerages.html.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply